Shulov Innovative Science (SIS) is an advanced clinical-stage biopharmaceutical company focusing on developing New Chemical Entities (NCE’s) for a variety of therapeutic uses. The NCE’s are short synthetic peptides with a unique pharmacological activity of combined potency as an effective anti-inflammatory, anti-viral, and analgesic agent. The NCE’s under development are short synthetic peptides branded as ZEP-3 and ZEP-4, and both molecules possess the unique biological activity and potent therapeutic use for a wide range of clinical indications.
The company completed a Phase II clinical study in Herpes Labialis (Cold sores) and has approached the FDA in preparation for a pre-IND meeting to secure an IND submission for an advanced Phase III clinical trial in Herpes Labialis patients in the US. It is the next step towards regulatory approval for the marketing and commercialization of its lead compound.
In addition, SIS conducts a Phase II clinical study in Atopic Dermatitis (AD), a common and underserved dermatological disorder, in 9 clinical sites at the leading dermatology departments at hospitals and community clinics in Israel.
SIS is developing additional clinical indications such as Herpes Zoster, Genital Herpes, Burns, and Lung Inflammation. Pre-clinical work is complete, and the company is ready to start a Phase I/II study on each of these indications.